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Abstract  
Background 
The endocrine disrupting chemical Bisphenol A (BPA) is widely used in food and beverage 
packaging.  Higher urinary BPA concentrations (uBPA) were cross-sectionally associated 
with heart disease in NHANES 2003/04 and NHANES 2005/6, independent of traditional 
risk factors.    
 
Methods and Results  
We included 758 incident coronary artery disease (CAD) cases and 861 controls followed for 
10.8 yrs from the European Prospective Investigation of Cancer – Norfolk UK.  Respondents 
aged 40-74 yrs and  free of CAD, stroke or diabetes provided baseline spot urine samples.  
 
uBPA concentrations (median value 1.3 ng/mL) were low. Per standard deviation (4.56ng/ml) 
increases in uBPA concentration were associated with incident CAD in age, sex and urinary 
creatinine adjusted models (n=1919, OR=1.13 95% CI 1.02 to 1.24, p=0.017). With CAD 
risk factor adjustment (including education, occupational social class, BMI category, systolic 
blood pressure, lipid concentrations and exercise) the estimate was similar but narrowly 
missed two-sided significance (n=1744 OR=1.11 CI: 1.00 to 1.23, p=0.058). Sensitivity 
analyses with the fully adjusted model, excluding early CAD (<3 year follow up); those with 
BMI>30; abnormal renal function; or adjusting additionally for vitamin C; C-reactive protein; 
or alcohol consumption, all produced similar estimates and all showed associations at p≤0.05.  
 
Conclusions 
Associations between higher BPA exposure (reflected in higher urinary concentrations) and 
incident CAD during over ten years of follow-up showed similar trends to previously 
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reported cross-sectional findings in the more highly exposed NHANES respondents. Further 
work is needed to accurately estimate the prospective exposure response curve and to 
establish the underlying mechanisms.   
 
Keywords: Coronary Artery disease, bisphenol A, endocrine disruption, body mass index, 
blood lipids 
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INTRODUCTION 
Bisphenol A (BPA) is one of the world’s highest production volume chemicals,1 used in 
polycarbonate plastics in many consumer products and epoxy resins lining food and beverage 
containers. BPA is an endocrine disrupting chemical (EDC) first synthesized with a novel 
estrogenic molecular structure in the 1930s.2 The American Endocrine Society3 have called 
for further research on EDCs including BPA, citing a strong basis for concern about possible 
links between EDCs, obesity and related disorders.  
 
The global population is subject to repeated exposure to BPA, primarily through packaged 
food but also through drinking water, dental sealants, dermal exposure and inhalation of 
household dusts4 with detectable concentrations of metabolites in the urine of > 90 % of the 
population worldwide.5, 6 In the first major epidemiological analysis of adult health effects 
associated with BPA, we studied 1455 adults aged 18 to 74 years with measured urinary BPA 
(uBPA) from the US National Health and Nutrition Survey (NHANES) 2003-2004.7-9We 
found higher BPA concentrations were associated with cardiovascular diagnoses (OR per one 
SD increase in BPA concentration 1.39, 95% CI 1.18-1.63; p=0.001 with full adjustment: the 
survey weighted standard deviation of uBPA was SD=6.68 ng/ml and the geometric mean 
2.47ng/ml (data from authors). With the release of new (independent) data from NHANES 
2005/06 (n=1493) we replicated the association of higher uBPA concentrations with coronary 
heart disease (OR per Z score increase in BPA 1.33, 95% CI: 1.01-1.75, p=0.043), despite a 
significant decrease in NHANES sample uBPA concentrations since the 2003/04 survey 
(NHANES 2005/6 geometric mean 1.79 ng/ml, 95% CI: 1.64 to 1.96). Initially reported 
associations with diabetes and some liver enzyme changes did not reach significance in the 
2005-2006 data, but remained significant in pooled data.9   
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These analyses were cross-sectional and it is theoretically possible, for example, that 
participants with CAD change their exposures to BPA (perhaps through change of diet) after 
diagnosis. Longitudinal data demonstrating temporality i.e. higher BPA concentrations 
predicting subsequent first diagnoses of disease would greatly strengthen the evidence for 
BPA playing a causal role.10, 11 
 
Our aim was to estimate the prospective association between uBPA and incident coronary 




We undertook a nested case-control analysis, measuring uBPA in stored samples from a 
baseline clinical examination. We compared uBPA concentrations in a case group who later 
developed coronary artery disease to a control group who remained CAD free during follow-
up.   
 
Study cohort 
We studied respondents in a well-characterized nested coronary artery disease case-control 
set within the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk 
cohort study12 EPIC-Norfolk is a prospective population study of 25,663 men and women 
aged between 45 and 79 years, resident in Norfolk, United Kingdom, who completed a 
baseline questionnaire and attended a clinic examination.13 The sample was comparable to 
UK national population samples with respect to many characteristics.13 Participants were 
recruited by post from age-sex registers of general practices. The baseline sample collection 
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was completed between 1993 and 1997; participants completed a detailed health and lifestyle 
questionnaire, and additional data collection was performed by trained nurses at a clinic visit 
as described previously. The Norwich District Health Authority Ethics Committee approved 
the study, and all participants gave signed informed consent.  
 
Participants  
Boekholdt et al12 selected a CAD case-control set within EPIC-Norfolk, originally with two 
controls matched to each case by sex, age (within 5 years), and date of clinic visit (within 3 
months). We used the Boekholdt12 cases and controls, but included only those aged 40 to 74, 
free of diabetes at baseline, with an available urine sample and valid uBPA measure. We 
selected equal numbers of incident CAD cases and controls, but the above constraints 
(especially urine sample availability) did not always allow selection within the Boekholdt 
original matching (see statistical analysis). Diabetes was excluded (n=84) as associations 
between uBPA and diabetes have been reported.9: We excluded those aged 75 plus to 
minimize biases caused by co-morbidity and non-representation of seniors in institutions, as 
with our previous NHANES analyses.  
Coronary artery disease endpoints 
Participants were identified as having CAD during follow-up if they had a recorded hospital 
admission and/or died with CAD as an underlying cause during follow-up. All EPIC-Norfolk 
participants were flagged for death certification at the UK Office of National Statistics14 and 
vital status is obtained for the whole cohort. Participants admitted to a hospital are identified 
by their unique National Health Service number, which a local health authority in Norfolk 
links to the Hospital Episode Statistics (including hospital contacts throughout the country). 
Coronary artery disease is classified according to the International Classification of Diseases, 
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Ninth Revision codes 410 to 414 or International Statistical Classification of Diseases, 10th 
Revision codes I20 to I25. A case is considered if a participant had a hospital diagnosis and/or 
died of coronary heart disease during the follow-up. In 1996 the EPIC study conducted a 
validation study15 of CAD cases ascertained from death certificates and hospital admissions. 
Confirmation of the cause of death was sought in general practice and hospital notes or the 
post-mortem report. For CAD deaths identified from death certificates, the cause of death 
was coded as a definite CAD death, possible CAD death, or not a CAD death using standard 
WHO-MONICA criteria. Of 39 deaths, 38 were confirmed by inspection of the notes. For 
cases identified based on linkage with hospital admission databases, the admission diagnosis 
was evaluated by inspection of hospital notes. The event was then coded as a definite 
myocardial infarction, possible myocardial infarction, or not a myocardial infarction on the 
basis of the clinical history, electrocardiographic changes, and enzyme changes using 
standard criteria. All 26 patients with a hospital discharge diagnosis of myocardial infarction 
had either a definite or possible myocardial infarction by WHO-MONICA criteria. Follow-up 
occurred until first CAD onset or December 2003 (mean 6.8 years, SD 2.4, range 0.1 to 10.8 
years).  
 
Analysis of urinary BPA concentrations 
Study participants attended the research clinic and provided a urine sample between March 
1993 and April 1998. We followed WHO guidelines over study design to evaluate exposure 
to BPA using biomonitoring.16 Analysis of uBPA metabolites was undertaken in 2011 by 
Brixham Environmental Laboratory, Division of Analytical Chemistry (a division of 
AstraZeneca PLC) in compliance with Good Laboratory Practice, EU Directive 88/32/EEC. 
Because orally administered BPA is considered to be rapidly and completely excreted, urine 
is the body fluid most appropriate for biomonitoring assessment of BPA exposure. We 
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measured total (free and conjugated) urinary concentrations of BPA based on the methods 
employed by NHANES17 and adopted by the Division of Environmental Health Laboratory 
Sciences, National Centre for Environmental Health, Centers for Disease Control and 
Prevention (CDC) i.e. sample preparation and on-line solid-phase extraction (SPE) coupled 
with high performance liquid chromatography (HPLC)-isotope dilution tandem mass 
spectrometry (MS/MS) with peak focusing.  
 
The GLP compliant quality control system included reagent blanks and we confirmed that 
EPIC stored samples contained almost exclusively metabolized compound, showing minimal 
leaching of BPA from collection or storage vessels. Total (free and conjugated) urinary 
concentrations of BPA were obtained using online, solid-phase extraction (SPE) coupled with 
high performance liquid chromatography (LC)-isotope dilution tandem mass spectrometry 
(MS/MS) with peak focusing.18 Calibration was linear from 0.50-100 µg/L (R2 >0.996), limit 
of detection was <0.50 ng/ml uBPA, limit of quantification, 0.50 ng/ml uBPA, lowest 
calibration standard gave a signal height:noise ratio >10 (relative standard deviations <20%, 
all other standards <15%). 
 
Biochemical Analyses 
Non-fasting blood samples were taken by venepuncture into plain and citrate bottles.12 Blood 
samples were processed soon after baseline collection at the Department of Clinical 
Biochemistry, University of Cambridge, by Quotient (http://www.quotientbioresearch.com/) 
using an Olympus AU640 chemistry analyzer or stored at –80°C. Serum levels of total 
cholesterol, HDL-C, and triglycerides were measured in fresh plasma samples with the RA 
1000 (Bayer Diagnostics, Leverkusen, Germany), and LDL-C levels were calculated with the 
Friedewald formula.19 C-reactive protein (CRP) concentrations were later measured on 
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thawed baseline plasma from cases and controls. CRP levels were measured with a sandwich-
type ELISA in which polyclonal rabbit anti-CRP antibodies were used as catching antibodies 
and biotinylated monoclonal antibodies against CRP (Sanquin Research, Amsterdam) were 
used as the detecting antibody.20 Results were related to a standard that consisted of 
commercially available CRP (Behringwerke AG, Marburg). Researchers and laboratory 
personnel had no access to identifiable information and could identify samples by unique 
identifier only.  
 
Statistical analysis 
We applied a similar analysis approach to that we previously used in NHANES9: we assigned 
a value of 0.28 ng/mL to uBPA assays below the level of accurate detection (n=190 controls 
and 140 cases reassigned); respondents with ‘outlier’ BPA concentrations >80.1 ng/ml were 
excluded from the analyses; and we present per standard deviation of uBPA linear estimates 
of association with incident CAD, adjusted for markers of relative social privilege and 
conventional CAD risk factors.  
 
Logistic regression models were used to estimate log-odds ratios of case status as a linear 
function of standardized uBPA concentrations (z-scores). The original EPIC age, sex and 
clinic date matched case control sets12 were sometimes incomplete (mainly due to urine 
sample availability): there were 217/861 controls (25.2%) with no matched case and 251/758 
cases (33.1%) had no matched control. Controls with no matched case had higher uBPA 
concentrations (OR=1.41 CI 1.17 to 1.70, p<0.000), and were less likely to be obese 
(compared to normal weight OR = 0.04 CI 0.21 to 0.75, p=0.005) compared to controls with 
matched cases. Amongst cases without controls, there were fewer women (OR for women vs 
men 0.58 CI 0.37 to 0.90, p=0.014).  In our main analysis we therefore analyzed the case 
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controls groups without matching, and provide a sub-analysis for the matched sets, using 
conditional logistic regression.    
 
Regression models were adjusted for potential confounders, including socioeconomic 
markers which Calafat and colleagues17 reported to be associated with BPA concentrations, 
and urinary creatinine to account for urine concentration.21 Initial adjustment was for: age, 
sex, education (categorized no qualifications, O level or equivalent (15 years), A level or 
equivalent (17 years) and post school or degree qualifications); occupational social class 
(grouped into uncoded (unemployed etc.), professional, managerial, skilled non-manual, 
skilled manual, semiskilled, non-skilled) and urinary creatinine concentration in mg/dl. Fully 
adjusted models were additionally adjusted for Body Mass Index (BMI, measured weight in 
kilograms divided by the square of measured height in meters, categorized into: underweight 
(BMI <18.5), recommended (BMI 18.5 to 24.9), overweight (BMI 25.0 to 29.9), obese I 
(BMI 30.0 to 34.9), obese II (BMI 35.0 or above), and unknown BMI); smoking (never 
smoked, former smoker, current smoker); systolic blood pressure (mm/hg), total cholesterol, 
HDL- and LDL- cholesterol, triglyceride concentrations, and level of physical activity 
(Inactive, Moderately inactive, Moderately active, Active). 
 
Generalized additive models with penalized cubic regression splines22 were used to explore 
the functional form of the relationships between presence of a cardiovascular disease 
diagnosis and BPA concentration. These models provide a method of identifying departures 
from linearity in exposure-response relationships. Linearity was assessed by visual inspection 
of the estimated spline functions and by consideration of the “estimated degrees of freedom” 
(edf) for the smoothed BPA term. Values of the edf close to 1 were taken as evidence of 
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linearity. These models were fitted in the statistical software ‘R’ using the mgcv package for 
generalized additive modeling.   
 
Throughout, we tested our a-priori hypothesis of a positive association between uBPA 
concentration and CAD. However, following convention we have presented two sided p-
value estimates and 95% confidence intervals.  
 
RESULTS 
Data were available on 861 controls and 758 cases of incident CAD (total n=1619). The 
mean age of cases was 64.1±sd7.5 years and controls 63.8±sd7.3 years. There were 
marginally fewer males in the case group (62.0% vs 66.1% versus in controls) and fewer had 
never smoked (Table 1). As expected, CAD risk markers were associated with case status. 
Urinary BPA concentrations were relatively low.  The median uBPA concentration in 
controls was 1.24 ng/ml and in cases 1.35 ng/ml (geometric means 1.23 and 1.39 ng/ml 
respectively: 1.304 ng/ml combined): The distributions were strongly skewed with, for 
example, 12.5% (108/861) of the controls having uBPA concentrations ≥4 ng/ml, compared 
to 16.6% (126/758) of the cases. Amongst controls (Table 2), those with higher uBPA 
concentrations (top 50% >1.243 ng/ml, vs bottom 50%) tended to be less likely to be from 
professional or managerial occupational backgrounds but there were no other differences on 
demographic or CAD risks.   
 
In logistic models with case/control status as the dependent variable, per standard deviation 
(SD=4.56ng/ml uBPA) linear increases in uBPA concentration were associated with incident 
coronary artery disease in age, sex and urinary creatinine adjusted models (model B, table 3: 
Odds ratio per z-score=1.13 95% CI 1.02 to 1.24, p=0.017). This association remained after 
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additional adjustment for education and occupational groupings (model C, OR=1.14 CI 1.03 
to 1.26, p=0.021). With additional adjustment for CAD risk factors (as in model D), the 
central estimate was similar but narrowly missed conventional two-sided significance 
(n=1477, OR=1.11 CI 1.00 to 1.23, p=0.058). 
 
We fitted a generalized additive model with a cubic regression spline to explore the shape of 
the dose response curve. This provided marginal evidence of a linear relationship between 
standard deviation increases in BPA concentration and log-odds of cardiovascular disease (to 
4 standard deviations above the mean BPA concentration as in our earlier work9, Figure 1; 
edf=1.001; p-value for smoothed term=0.068; 6 knots placed at -0.5, -0.37, -0.26, -0.08, 0.26, 
3.92): a quadratic model did not provide a better fit (p=0.40) and inspection of residual plots 
for the linear and quadratic models did not suggest threshold effects.  
 
Sensitivity analyses 
We undertook post-hoc sensitivity analyses, using separate variations of the fully (CAD risk 
factor adjusted) model (Table 3, models E to K). We excluded the earliest three years of 
follow-up (to remove those close to CAD onset at uBPA sample collection, model E); we 
excluded those with a BMI≥30, given the suggestion that obesity may be a key factor (model 
F); we adjusted for vitamin C concentrations, a marker of dietary quality (particularly high 
fruit and vegetable intake, model G); we excluded those with elevated serum creatinine 
concentrations, mainly removing impaired renal function, which may result in biased uBPA 
measures (model H); adjusted for C reactive protein concentrations (reflecting inflammation) 
(model I); adjusted for liver enzymes to account for liver cell function effects (model J); 
adjusted for units of alcohol consumed at the time of baseline interview (model J). None of 
these analyses changed estimates materially, and all associations reached p≤0.05.   
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Finally, our cases and controls were originally drawn in matched sets on the basis of date of 
birth, sex and date of clinic visits categories. Due to the non-CAD risk based matching and 
limited availability of urine specimens, we ignored matching in the above: estimating a 
conditional (matched) logistic model on the subset with at least one matched pair, per SD 




In NHANES 2003/047 and again in NHANES 2005/06, higher uBPA concentrations were 
associated with heart disease (pooled p-value<0.001).9 A major limitation of the NHANES 
analyses is their cross-sectional nature, making it theoretically possible, for example, that 
CAD patients might have changed their behaviors and incidentally increased their BPA 
exposure. To strengthen the evidence for causal inference we conducted the longitudinal 
study presented here, which provides the first report of similar trends in associations between 
higher BPA exposure (evidenced as higher uBPA metabolite concentrations) and incident 
CAD. The prospective design adopted shows that such reverse causation cannot account for 
BPA - CAD associations.  
 
The concentrations of uBPA seen in this sample are relatively low: the overall median value 
was 1.3 ng/ml, compared to 2.7 ng/ml (inter-quartile range 1.3 to 5.4 ng/mL) in the US 
NHANES 2003/4 study in which the uBPA association with cardiovascular disease was first 
identified.23 The relative paucity of more highly exposed study subjects clearly reduces our 
power to detect true associations, which makes our results more noteworthy. This reduced 
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power may explain the marginal loss of two sided significance for the fully adjusted 
unmatched linear model. In our NHANES 03/04 analysis uBPA SD= 6.68 ng/ml and 
produced a per SD OR=1.39, 95% CI 1.18-1.63; p=0.001 for reported cardiovascular 
diagnoses in fully adjusted models. Scaling our current prospective study result (EPIC OR 
raised to the power of NHANES SD/EPIC SD), the EPIC per 6.68 ng/ml uBPA OR=1.17 
95%CI 1.00 to 1.35, p=0.058 for incident CAD. Thus, associations between higher uBPA 
concentrations and incident CAD in EPIC-Norfolk showed similar although somewhat 
smaller trends compared to the cross-sectional results in NHANES 03/04. 
 
The BPA measures in EPIC-Norfolk (as in NHANES) are from single spot urine specimens: 
ingested BPA in humans is rapidly excreted; hence the use of urine in biomonitoring.5 We 
used urine samples taken at the same time of day for each respondent to minimize inter-
individual variation. Regarding the use of single spot samples as measures of longer term 
exposure, a study of temporal variability found a single spot sample had moderate sensitivity 
for predicting an individual’s tertiary BPA categorization.24 Nepomnaschy et al25 measured 
stability of BPA over 2 week intervals in first voided urine samples from 60 women and 
found a Spearman correlation of 0.5, indicating that within-individual BPA exposures were 
generally stable over periods of weeks. Ye et al26 similarly reported changes between spot 
measures during each day and across 7 days, but concluded that spot samples may adequately 
reflect population average exposures.  
Whilst humans can rapidly eliminate BPA when it is provided as a single bolus27 continuous 
external BPA exposure through diet appears to lead to sustained concentrations that are 
detectable in serum or plasma. A recent study using deuterated BPA found the half life of 
BPA was six times longer for diet-fed mice than those who received a bolus, a phenomenon 
consistent with an inhibitory effect of food on first pass metabolism.28 Stahlhut et al29 
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reported the population half life of BPA to be considerably longer than six hours, based on 
NHANES data on fasting times. The supposition is that BPA, which is lipophilic, is 
redistributing to lipid rich tissues, from which slow release may occur.  
 
However, there is an absence of human pharmacokinetic data for BPA to fully explain these 
findings and extrapolations from animal studies have been hindered by species-specific 
differences in the metabolism and toxicity of BPA30 and by the multiple potential routes by 
which humans may be exposed, including dermal exposure31 and inhalation of dusts, which 
would avoid first-pass metabolism. Once ingested, BPA is metabolized in the intestines and 
liver,32 with the major metabolite BPA-monoglucuronide eliminated in humans via urine, but 
in rats via bile. Glucuronidation and enterohepatic recirculation also show differences 
between rodents, primates and humans, although the effect of this on pharmacokinetics is not 
yet clear.33 
 
It should be noted that any misclassification of longer term BPA body burden is likely to 
have resulted in a smaller (diluted) estimate of the strength of association between BPA and 
CAD: the true association is likely to be stronger. Some34 have suggested that BPA disease 
associations are driven by higher dietary intakes, which would result in obesity related risks 
and incidental higher BPA excretions. However, our sensitivity analyses show that exclusion 
of those with obesity and adjustment for blood lipid concentrations and levels of physical 
activity have little effect on the association, making such an explanation unlikely. Similarly 
the lack of effect of adjustment for vitamin C makes diets poor in fruit and vegetables an 
unlikely explanation.35 Liver and kidney function changes, resulting in altered BPA 
metabolism or excretion, are also possible confounding factors, but excluding those with high 
blood creatinine concentrations or adjusting for liver enzymes sensitive to cell damage show 
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these as unlikely explanations. In any observational study it is impossible to exclude the 
possibility that some unmeasured confounder is present. It is clear, however, that any such 
confounder must be independent of classical CAD risk factors.  
 
There are several potential mechanisms by which BPA could plausibly raise CAD incidence 
rates. BPA and metabolites have well-documented estrogenic, anti-androgenic36 and 
additional receptor-mediated modes of toxicity. 36 Given the known receptor-mediated effects 
of estrogen on cardiovascular tissues, it is biologically plausible that BPA might exert 
estrogenic effects or antagonize endogenous estrogens in cardiovascular tissues by binding to 
soluble or membrane bound estrogen receptors.37  
 
The mean uBPA concentration in our study was 3.65 ng/ml. Taking an average 24 hour urine 
volume for adults to be 1600ml, and assuming an 100% excretion rate and a total blood 
volume of 6 litres, this would give an estimated BPA blood concentration in the ng/ml range. 
BPA shows relatively weak estrogenic agonist activities against both human estrogen 
receptor alpha and beta subtypes (ERα, ERβ) that control many estrogen-mediated activities.  
The IC50 for receptor binding of BPA to human ERα and ERβ is in the low micromolar 
range when calculated in vitro and if extrapolated directly to the in vivo situation (without 
considering competitive binding to serum binding proteins, for instance), this would imply 
low ER receptor occupancy rates in blood and potential target tissues.  However, BPA binds 
to other estrogen-related receptors with high affinity, including the estrogen related receptor 
gamma (ERRγ), for which optimal receptor binding is in the nanomolar range 38. A recent 
study has reported positive associations between increased BPA exposure and in vivo 
estrogenic gene expression in adults, including ERβ and the estrogen related receptor 
alpha,ERRα.39 ERRα is an orphan nuclear receptor involved in estrogenic signaling and 
  17 
energy homeostasis that is coordinately regulated with ERRγ. It is relevant to note that 
expression of ERRα is highest in tissues that preferentially use fatty acids as energy sources, 
including adipose tissue, skeletal muscle and heart.   
 
In addition to its estrogenic mode of action, BPA has been shown to possess anti-androgenic 
activity40, and uBPA levels have been associated with higher blood testosterone 
concentrations in Italian men18. Lee et al.40 showed BPA to affect multiple steps in the 
activation and function of the androgen receptor. Conversely, the enzyme responsible for 
BPA conjugation in the intestine and liver, uridine diphosphate-glucuronosyl transferase 
(UGT) is itself downregulated by androgens41, which could result in an increase in serum 
BPA concentration under hyperandrogenic conditions. It is unlikely that such metabolic 
change could alter 24-hr urinary BPA excretion in the context of repeated ingestion of BPA 
at the population level, although it has been suggested that a combination of 
hyperandrogenemia and insulin resistance may further enhance BPA levels in younger 
populations, especially in women with syndromes associated with increased CVD markers 
and CVD42. The relationship between androgen homeostasis and cardiovascular risk remains 
to be comprehensively established, although an increased risk of cardiovascular adverse 
events was recently reportedly in a trial of testosterone supplementation in older men43.  
 
Because the pharmacokinetic behavior of BPA in humans is not comprehensively 
documented for practical and ethical reasons, it is not possible to rule out the conversion of 
BPA to metabolites that show enhanced estrogenic activity. The major metabolite of BPA, 
BPA-monoglucuronide has no estrogenic activity, but oxidative cleavage of BPA to form the 
estrogenically active metabolite 4-methyl-2,4-bis (4-hydroxyphenyl)pent-1-ene (MBP) has 
been shown in rat liver. MBP was 500 fold more potent as an inducer of dose-dependent 
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changes of estrogen receptor genes in vivo compared with BPA itself44. The extent to which 
MBP may be present in humans is not known, but the oxidation product BPA-catechol, which 
also shows estrogenic activity, is reported to be a minor (approximately 10%) metabolite in 
both human and rat microsomal models. Given these potential contributory factors, a 
comprehensive documentation of BPA phase 1 metabolism is clearly merited.   
  
There are other potential mechanisms of BPA toxicity that may be relevant to the results 
presented here. Maxi-K channels and the β1 subunit in particular45 play key roles in 
regulating smooth muscle excitability and are estrogen sensitive. BPA in the micromolar 
range activates Maxi-K (KCa1.1) ion channels in human coronary smooth muscle cells in 
culture, sufficient to hyperpolarize the membrane potential.46 Laboratory exposure studies 
have shown that BPA can induce liver and oxidative cellular damage,47 disrupt pancreatic β 
cell function,48 and have obesity-promoting effects, 49 all of which could plausibly contribute 
towards CAD risk. Certain BPA derivatives including bisphenol A diglycidyl ether (BADGE) are 
peroxisome proliferation activated receptor gamma (PPARγ) antagonists.50 PPARγ agonists 
may activate or inhibit ion channel activity in vessel walls directly,51 providing an alternative 
mechanism worthy of further investigation. 
 
Much remains unknown about the mechanisms involved in the BPA CAD association in 
humans. Future scientific work in humans is, of course, constrained by ethical limits and the 
practicality of repeated BPA exposure measures, long term and larger follow-up studies. 
Without these constraints, controlled trials would be needed to prove causation in humans, 
but such evidence is almost certainly beyond reach.  
 
Conclusion  
  19 
Associations between higher BPA exposure (reflected in higher urinary concentrations) and 
incident CAD during over ten years of follow-up in the EPIC-Norfolk study showed similar 
trends to previously reported cross-sectional findings in the more highly exposed NHANES 
03/04 and 05/06 study respondents. More work is needed to accurately estimate the shape of 
the dose-response relationship. Work is also needed to identify the mechanism underlying the 
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Figure 1: Dose response curves for the association of BPA concentration (per standard 
deviation increase (4.56 ng/ml) with logged odds of incident coronary artery disease. 
Generalized additive models with cubic regression splines in EPIC-Norfolk, for uBPA range 
to 4 standard deviations from mean. 
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Table 1. Socio-demographic and risk factor characteristics of the cases (with incident 
coronary artery disease) and controls   
  Controls  (sd)  Cases  (sd) p value 
Number 861   758   
Age (years) 63.8 (7.3)  64.1 (7.5) 0.412 
Male sex 62.0%   66.1%  0.088 
       
Educational attainment*      9.4*10-4 
No qualifications (<15 years of 
schooling)  38.6%  
 44.0%   
‘O’ levels or equivalent (15 yrs) 8.1%   7.7%   
‘A’ level or equivalent (17yrs) 40.2%   41.0%   
Post school or degree qualification  13.1%   7.3%   
       
Occupational social class      0.010 
Professional  8.1%   5.2%   
Managerial  36.2%   34.6%   
Skilled non-manual  16.6%   15.9%   
Skilled manual  23.4%   22.6%   
Semi-skilled 11.9%   15.3%   
Non-skilled 3.3%   5.7%   
  uncoded 0.5%   0.7%   
       
Smoking status      2.3*10-8 
  current 9.6%   17.1%   
  past 46.4%   51.5%   
  Never   43.9%   31.5%   
       
Physical activity      0.0029 
  Inactive 31.2%   39.5%   
  Moderately inactive 27.9%   25.7%   
  Moderately active 22.4%   21.8%   
  Active 18.5%   14.1%   
       
BMI kg/m2 26.2 (3.4)  27.2 (3.8) 2.5*10-9 
LDL-C, mmol/l (n=1532) 4.1 (1.0)  4.3 (1.0) 5.1*10-6 
HDL-C, mmol/l (n=1532) 1.4 (0.4)  1.3 (0.4) 1.5*10-9 
Total cholesterol (n=1595) 6.33 (1.19)  6.56 (6.47) 5.5*10-5 
Triglycerides (n=1594) 1.91 (1.32)  2.18 (1.13) 6.0*10-6 
Systolic blood pressure, mm Hg 
(n=1615) 137.5 (17.8) 
 143 (18.7) 2.6*10-10 
       
Urinary Bisphenol A concentration 
(ng/mL) (n=1619)   
    
     Median  
     (25th to 75th percentile)  
1.24 
(0.59 to 2.52)   
1.35 
(0.67 to 2.70)    0.042
+
 
 Geometric mean  1.23 (2.95)  1.39 (3.02) 0.027 
Notes: Data are presented as arithmetic mean (SD), or %    
Means, percentages may be based on marginally fewer observations than the indicated number of 
subjects; * one case had unknown educational status. + Mann-Whitney rank sum test 
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Table 2: Socio-demographic and coronary artery disease risk factor status by lower and 










(sd) Unadjusted p-value* 
N 842  842   
Age (years) 63.8 (7.19) 63.8 (7.38) 0.91 
Male sex 62.9%  62.8%  0.99 
      
Smoking status     0.42 
  Never  8.1%  10.5%   
  Past 48.5%  45.9%   
  current 43.5%  33.8%   
      
Education      0.072 
No qualifications (<15 years of 
schooling)  36.9%  42.0%   
‘O’ levels or equivalent (15 yrs)  6.7%    9.6%   
‘A’ level or equivalent (17yrs) 41.9%  37.0%   
Post school or degree qualification  15.6%  11.5%   
      
Occupational Social class     0.034 
Professional   8.3%    7.8%   
Managerial  40.3%  32.1%   
Skilled non-manual  15.0%  17.8%   
Skilled manual  21.6%  25.2%   
Semi-skilled 10.0%  14.0%   
Non-skilled  4.6%  2.5%   
  Uncoded  0.2%  0.7%   
      
Physical activity     0.49 
  Inactive 30.5%  34.6%   
  Moderately inactive 29.2%  26.3%   
  Moderately active 23.0%  20.9%   
  Active 17.4%  18.3%   
      
Body Mass Index  categories (kg/m2     0.21 
  <18.4 0.43%    0.0%   
  18.4 to 24.9 38.2%  33.7%   
  25.0 to 29.9 47.0%  52.8%   
  30.0 to 34.9 12.9%  11.3%   
  >35   1.5%    2.2%   
      
LDL-Cholesterol, mmol/l 4.06 (1.04) 4.11 (0.97) 0.45 
HDL-Cholesterol, mmol/l 1.36 (0.39) 1.36 (0.41) 0.93 
Total cholesterol, mmol/l  6.31 (1.30) 6.28 (1.08) 0.78 
Triglycerides, mmol/l  2.03 (1.68) 1.87 (1.02) 0.097 
Systolic blood pressure, mm Hg 138.4 (16.6) 137.8 (17.6) 0.59 
Note Data are presented as arithmetic mean (SD), or % 
* Unadjusted chi squared or t-test estimate
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Table 3. Logistic regression estimates of odds ratios (95% CI) per standard deviation 
increase in uBPA concentrations (SD=4.56ng/ml) with incident coronary artery disease  
Model model definition  OR 95% CI p 
Hypothesis testing    
A Age, sex (n=1619) 1.13 1.02 to 1.24 0.018 
B age, sex, urinary creatinine (n=1619) 1.13 1.02 to 1.24 0.017 
C B plus education level and occupational group (n=1579) 1.14 1.03 to 1.26 0.012 
D C plus cardiovascular risk factors* (n=1477) 1.11 1.00 to 1.23 0.058 
Post-hoc sensitivity analyses    
E D excluding the earliest three years of follow-up (n=1350) 1.12 1.00 to 1.26 0.050 
F D including obesity (BMI>30, remaining n=1273) 1.24 1.02 to 1.49 0.028 
G D including serum creatinine (excluding serum creatinine>120 nmol/l, n=963) 1.18 1.05 to 1.35 0.008 
H 
 
D with additional adjustment for serum vitamin C 
concentration (excluding <23 nmol/L, included 
n=1308) 
1.17 1.03 to 1.33 0.017 
I 
 
D with additional adjustment for high sensitivity CRP 
concentration (n=1027)  
1.16 1.03 to 1.30 0.017 
J 
 
D with additional adjustment for gamma-
glutamyltransferase and alanine aminotransferase 
concentrations: (n=1055) 
1.14 1.02 to 1.28 0.021 
K 
 
D with additional adjustment for alcohol intake at 
baseline (volume units) (n=1582) 
1.13 1.01 to 1.25 0.027 
See methods for coding of covariates. Numbers vary due to missing data on specific 
measures. *adjusted as in C and with the additional variables: Body mass index, cigarette 
smoking, average of the two systolic BP readings in mmHg, total cholesterol, LDL and HDL 
cholesterol, triglycerides and level of physical activity.  
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Figure 1 
 
